Treovir
Phase 2Treovir’s G207 Therapy demonstrated improved survival in a Phase 1 study without any serious side effects. Treovir strives to change the course of brain tumor therapies, improve survival rates and quality of life and provide hope.
Founded
2016
Focus
Biologics
About
Treovir’s G207 Therapy demonstrated improved survival in a Phase 1 study without any serious side effects. Treovir strives to change the course of brain tumor therapies, improve survival rates and quality of life and provide hope.
Funding History
1Total raised: $30M
Series A$30MMPM CapitalNov 15, 2020
Company Info
TypePrivate
Founded2016
LocationSan Diego, United States
StagePhase 2
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile